Cognition Therapeutics, Inc.
CGTXNASDAQHealthcare● Active
$1.21
$-0.08(-6.20%)
Market Cap$89034451
P/E Ratio—
52W High$3.83
52W Low$0.25
Cognition Therapeutics, Inc. (CGTX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CGTX · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.05
Est. -$0.06 · +16.7%
Revenue
—
Est. $0.00B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS🔥 4-Quarter EPS Beat Streak
CGTX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.06 | — | — | — | $0.01B | — |
| ▲ Q2 FY2026 | May 7, 2026 | -$0.06 | -$0.05 | +16.7% | — | $0.00B | — |
| ▲ Q1 FY2026 | Mar 26, 2026 | -$0.06 | -$0.02 | +66.7% | — | — | — |
| ▲ Q4 FY2025 | Nov 6, 2025 | -$0.07 | -$0.06 | +14.3% | — | — | — |
| ▲ Q3 FY2025 | Aug 7, 2025 | -$0.12 | -$0.11 | +8.3% | — | — | — |
| ▼ Q2 FY2025 | May 7, 2025 | -$0.12 | -$0.14 | -16.7% | — | — | — |
| ▼ Q1 FY2025 | Mar 20, 2025 | -$0.16 | -$0.17 | -6.3% | — | — | — |
| ▼ Q4 FY2024 | Nov 13, 2024 | -$0.24 | -$0.25 | -4.2% | — | — | — |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.06
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
-$0.05
EPS Est.
-$0.06
EPS Surpr.
+16.7%
Revenue
—
Q1 FY2026
Mar 26, 2026Beat
EPS Actual
-$0.02
EPS Est.
-$0.06
EPS Surpr.
+66.7%
Revenue
—
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
-$0.06
EPS Est.
-$0.07
EPS Surpr.
+14.3%
Revenue
—
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
-$0.11
EPS Est.
-$0.12
EPS Surpr.
+8.3%
Revenue
—
Q2 FY2025
May 7, 2025Miss
EPS Actual
-$0.14
EPS Est.
-$0.12
EPS Surpr.
-16.7%
Revenue
—
Q1 FY2025
Mar 20, 2025Miss
EPS Actual
-$0.17
EPS Est.
-$0.16
EPS Surpr.
-6.3%
Revenue
—
Q4 FY2024
Nov 13, 2024Miss
EPS Actual
-$0.25
EPS Est.
-$0.24
EPS Surpr.
-4.2%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.05 | $-0.05 | $-0.05 | 1 |
| Q3 FY2027 | $-0.05 | $-0.05 | $-0.05 | 1 |
| Q2 FY2027 | $-0.05 | $-0.05 | $-0.05 | 1 |
| Q1 FY2027 | $-0.05 | $-0.05 | $-0.05 | 1 |
| Q4 FY2026 | $-0.13 | $-0.13 | $-0.13 | 1 |
| Q3 FY2026 | $-0.07 | $-0.07 | $-0.07 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +16.7% | $1.23 | $1.16 | -5.69% |
| ▲ Q1 FY2026 | Mar 26, 2026 | +66.7% | $1.11 | $1.08 | -2.70% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +14.3% | $1.69 | $1.66 | -1.78% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +8.3% | $0.71 | $0.68 | -4.78% |
| ▼ Q2 FY2025 | May 7, 2025 | -16.7% | $0.42 | $0.35 | -15.04% |
| ▼ Q1 FY2025 | Mar 20, 2025 | -6.3% | $0.45 | $0.43 | -5.18% |
| ▼ Q4 FY2024 | Nov 13, 2024 | -4.2% | $0.60 | $0.54 | -10.24% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +18.2% | $0.58 | $0.58 | +0.46% |
Q2 FY2026-5.69%
Report Date
May 7, 2026
EPS Beat/Miss
+16.7%
Price Before
$1.23
Price After
$1.16
Q1 FY2026-2.70%
Report Date
Mar 26, 2026
EPS Beat/Miss
+66.7%
Price Before
$1.11
Price After
$1.08
Q4 FY2025-1.78%
Report Date
Nov 6, 2025
EPS Beat/Miss
+14.3%
Price Before
$1.69
Price After
$1.66
Q3 FY2025-4.78%
Report Date
Aug 7, 2025
EPS Beat/Miss
+8.3%
Price Before
$0.71
Price After
$0.68
Q2 FY2025-15.04%
Report Date
May 7, 2025
EPS Beat/Miss
-16.7%
Price Before
$0.42
Price After
$0.35
Q1 FY2025-5.18%
Report Date
Mar 20, 2025
EPS Beat/Miss
-6.3%
Price Before
$0.45
Price After
$0.43
Q4 FY2024-10.24%
Report Date
Nov 13, 2024
EPS Beat/Miss
-4.2%
Price Before
$0.60
Price After
$0.54
Q3 FY2024+0.46%
Report Date
Aug 8, 2024
EPS Beat/Miss
+18.2%
Price Before
$0.58
Price After
$0.58
Avg Beat Reaction-2.90%
Avg Miss Reaction-10.15%
Beat Rate5 / 8 quarters
Largest Move-15.04% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CGTX ends December
Cognition Therapeutics, Inc. (CGTX) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.05 — beating the analyst consensus of $-0.06 by +16.7%. CGTX has beaten EPS estimates for 4 consecutive quarters. The next CGTX earnings date is expected around September 1, 2026.
Each quarter, investors track CGTX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CGTX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CGTX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CGTX earnings · 5 questionsCognition Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. CGTX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CGTX historically reports after market close (AMC).
CGTX earnings datewhen is CGTX earningsCGTX next earnings datewhen does CGTX report earningsCGTX earnings calendar
▸ Source: FMP · Cognition Therapeutics, Inc. SEC filings · US GAAP · Cognition Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026